President and Chief Executive Officer
Jon brings well over 30 years’ experience of successfully developing new medical technologies and building successful companies. Prior to Neograft, Jon was CEO of LumeRx, a venture-backed gastroenterology startup, VP of R&D and Operations at Biosphere Medical (acquired by Merit Medical); VP of R&D and Operations at Urologix (ULGX), and VP of R&D at Pfizer/Schneider (acquired by Boston Scientific). He cofounded Harbor Medical (acquired by Teleflex) and held several positions of increasing responsibility at Medi Tech (now Boston Scientific).
At LumeRx, Jon led the development and clinical testing of a novel light-based system to treat H pylori, the stomach bacteria that causes most stomach ulcers and cancers. Jon led a multinational team at Biosphere Medical that developed several generations of vascular embolic particles and delivery catheters. His team also achieved the first FDA approval of a transvascular treatment for uterine fibroids. At Urologix (ULGX), Jon spearheaded development of a transurethral microwave delivery system that treated BPH (benign prostate hyperplasia). Jon also led a multinational team at Pfizer/Schneider (acquired by Boston Scientific) developing interventional cardiology products. Jon’s team developed dozens of new products achieving revenues in the hundreds of millions within five years. Before that he cofounded Harbor Medical (acquired by Teleflex) that focused on vascular access devices. He began his career in R&D and operations at Medi Tech (now Boston Scientific). Jon has a B.S. in Physics from the University of Vermont.
Mohammed El-Kurdi, PhD.
Co-founder, Director, Research
Dr. El-Kurdi co-founded the company in 2009. He has been focused on bioengineering arterial vein grafts since 2000, beginning shortly after he joined a cardiovascular research team at the University of Pittsburgh’s McGowan Institute for Regenerative Medicine. His PhD work focused on Neograft’s core technology that formed the foundation of the company and its central intellectual property. This work also resulted in the first peer reviewed publication of the product. Several generations later, the company has evolved a product that delivers on the promise of his early research to produce a stable and self-supporting arterial vein graft.